KR20200109071A - Composition for preventing, improving or treating hair loss comprising apolipoprotein e - Google Patents
Composition for preventing, improving or treating hair loss comprising apolipoprotein e Download PDFInfo
- Publication number
- KR20200109071A KR20200109071A KR1020190028105A KR20190028105A KR20200109071A KR 20200109071 A KR20200109071 A KR 20200109071A KR 1020190028105 A KR1020190028105 A KR 1020190028105A KR 20190028105 A KR20190028105 A KR 20190028105A KR 20200109071 A KR20200109071 A KR 20200109071A
- Authority
- KR
- South Korea
- Prior art keywords
- hair loss
- apolipoprotein
- hair
- present
- apoe
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 99
- 208000024963 hair loss Diseases 0.000 title claims abstract description 93
- 230000003676 hair loss Effects 0.000 title claims abstract description 81
- 101710095339 Apolipoprotein E Proteins 0.000 title claims abstract description 64
- 102100029470 Apolipoprotein E Human genes 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 25
- 230000002611 ovarian Effects 0.000 claims abstract description 24
- 239000000411 inducer Substances 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 18
- 230000009245 menopause Effects 0.000 claims abstract description 15
- 238000009806 oophorectomy Methods 0.000 claims abstract description 13
- 230000008717 functional decline Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 16
- 230000003752 improving hair Effects 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000003658 preventing hair loss Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 208000024891 symptom Diseases 0.000 abstract description 15
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- -1 ethyl oleate Chemical class 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- HSQAARMBHJCUOK-UHFFFAOYSA-N n-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide Chemical compound OCCCNCCCC1=CC=C(Cl)C(C(=O)NCC23CC4CC(CC(C4)C2)C3)=C1 HSQAARMBHJCUOK-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 241000195940 Bryophyta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- NYPPCCZHHLGDBU-UHFFFAOYSA-N 2-(3-methoxypropyl)-2,4,4,6,6,8,8-heptamethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane Chemical compound COCCC[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 NYPPCCZHHLGDBU-UHFFFAOYSA-N 0.000 description 1
- XGSXUSCKTLWSLU-UHFFFAOYSA-N 3-[dimethyl(trimethylsilyloxy)silyl]propan-1-ol Chemical compound C[Si](C)(C)O[Si](C)(C)CCCO XGSXUSCKTLWSLU-UHFFFAOYSA-N 0.000 description 1
- GSSWFBLVISCYBP-UHFFFAOYSA-N 3-chloropropyl-dimethyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)CCCCl GSSWFBLVISCYBP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- AMNQQNTZDFYVGH-UHFFFAOYSA-N dimethyl-phenyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)C1=CC=CC=C1 AMNQQNTZDFYVGH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
Abstract
Description
본 발명은 아포지질단백질 E를 포함하는 탈모 예방, 개선 또는 치료용 약학 조성물, 건강기능식품 조성물 및 화장료 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing, improving or treating hair loss, including apolipoprotein E, a health functional food composition, and a cosmetic composition.
사람의 모발은 인간의 외모의 가장 중요한 측면 중 하나로 간주된다. 사람의 모발은 피부 및 두피를 보호하는 일차적인 역할뿐만 아니라, 사회적 및 성적 의사소통에 있어서 고유의 역할을 하므로 매우 중요하다. 탈모는 정상적으로 모발이 존재해야 하는 부위에 모발이 없는 상태를 말하거나 성장을 멈춘 모발이 자연스럽게 빠지는 현상을 의미하며, 일반적으로는 두피의 성모(굵고 검은 머리털)가 빠지는 것을 의미한다. 모발은 보통 하루에 50~100개 이상 정도가 빠지며, 머리가 빠지는 숫자가 많을수록 탈모증이라고 정의한다. 탈모는 인간에게 감정적으로 고통을 주는 질병으로, 여성의 탈모 또는 탈모증은 상당한 정서적 고통 및 불안과 마주하게 된다. Human hair is considered one of the most important aspects of human appearance. Human hair is very important because it plays a unique role in social and sexual communication as well as its primary role in protecting the skin and scalp. Hair loss refers to a state in which there is no hair in the area where the hair should normally exist, or refers to a phenomenon in which hair that has stopped growing naturally falls out, and generally refers to the loss of hair on the scalp (thick black hair). Hair loss is usually 50 to 100 or more per day, and the more hair falls out, the more it is defined as alopecia. Hair loss is a disease that causes emotional pain to humans, and alopecia or alopecia in women faces considerable emotional pain and anxiety.
이러한 탈모의 원인은 다양한데, 유전적 원인과 호르몬이 중요한 인자로 여겨지고 있으며, 그 중 에스트로겐(estrogen)이 여성 탈모의 위험을 높이는 호르몬으로 가장 주목받고 있다. 여성 호르몬인 에스트로겐은 모발 성장 인자를 활성화시키고 탈모 인자를 억제시켜 튼튼한 모발을 만드는데 중요한 역할을 하나, 에스트로겐의 과다 분비 또는 결핍에 의해 호르몬의 균형이 깨지면서 탈모를 유발한다. 특히, 여성의 갱년기(climacterium) 또는 폐경기(menopause)가 시작되면 난소의 기능 저하 및 실조로 난소에서 분비되는 여성 호르몬이 감소하게 되고, 이로 인해 탈모를 비롯한 여러 대사성 질환이 유발되며, 상대적으로 탈모를 유발하는 남성 호르몬인 안드로겐(androgen)의 분비는 증가하면서 탈모 위험을 더욱 높인다. There are various causes of such hair loss, and genetic causes and hormones are considered to be important factors, among which estrogen is attracting the most attention as a hormone that increases the risk of female hair loss. Estrogen, a female hormone, plays an important role in activating hair growth factors and inhibiting hair loss factors to make strong hair, but the balance of hormones is disrupted by excessive secretion or deficiency of estrogen, causing hair loss. In particular, when a woman's climacterium or menopause begins, female hormones secreted from the ovaries decrease due to ovarian function decline and ataxia, which induces various metabolic diseases, including hair loss, and relatively hair loss. The secretion of androgens, a male hormone that causes, increases, further increasing the risk of hair loss.
국내에서도 탈모 관련 많은 연구들이 진행되고 있고, 최근에는 육모 및 탈모 기전에 관여하는 많은 조절 인자들에 대한 연구가 활발히 진행되고 있다. 현재 시중에 유통되고 있는 발모 관련 제품들은 다양하고 많으나, 대부분 탈모 방지 및 발모 효과가 미비하거나 일시적이어서 사용자의 요구를 충족하지 못하고 있다. 또한, 상기 제품의 효능이나 안전성에 관한 근거 자료 또한 미흡하고, 상기 제품의 사용을 중단할 시에는 다시 탈모증이 재발되거나 성기능 장애가 발생하는 등 심각한 부작용 등이 보고되면서 사용에 어려움을 겪고 있는 실정이다.There are many studies related to hair loss in Korea, and recently, studies on many regulatory factors involved in hair growth and hair loss mechanisms have been actively conducted. Currently, there are various and many products related to hair growth on the market, but most of the hair loss prevention and hair growth effects are inadequate or temporary, and thus cannot meet the needs of users. In addition, the evidence for the efficacy or safety of the product is insufficient, and when the use of the product is discontinued, serious side effects such as recurrence of alopecia or sexual dysfunction are reported, making it difficult to use.
따라서 독성이나 부작용이 적으며 효과가 뛰어난 탈모 치료제의 개발이 시급한 실정이다.Therefore, there is an urgent need to develop a hair loss treatment that has little toxicity or side effects and is effective.
상기와 같은 문제점을 해결하기 위해, 본 발명은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 포함하는 탈모 예방 또는 치료용 약학 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating hair loss, including apolipoprotein E (ApoE) or an inducer thereof.
본 발명은 아포지질단백질 E 또는 이의 유도제를 포함하는 탈모 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or improving hair loss comprising apolipoprotein E or an inducer thereof.
본 발명은 아포지질단백질 E 또는 이의 유도제를 포함하는 탈모 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving hair loss comprising apolipoprotein E or an inducer thereof.
또한, 본 발명은 아포지질단백질 E를 이용한 탈모 개선제 스크리닝 방법을 제공한다.In addition, the present invention provides a method for screening a hair loss improving agent using apolipoprotein E.
본 발명에 따른 탈모 예방 또는 치료용 약학 조성물은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유할 수 있다.The pharmaceutical composition for preventing or treating hair loss according to the present invention may contain apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에 따른 탈모 예방 또는 개선용 건강기능식품 조성물은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유할 수 있다.The health functional food composition for preventing or improving hair loss according to the present invention may contain apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에 따른 탈모 예방 또는 개선용 화장료 조성물은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유할 수 있다.The cosmetic composition for preventing or improving hair loss according to the present invention may contain apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에 따른 탈모 개선제 스크리닝 방법은 인체에서 분리된 생물학적 시료에 시험물질을 처리하는 단계; 상기 시험물질을 처리한 시료에서 아포지질단백질 E(Apolipoprotein E; ApoE) 발현 수준을 측정하는 단계; 및 상기 발현 수준을 상기 시험물질을 처리하지 않은 대조군에서의 아포지질단백질 E의 발현 수준과 비교하여, 상기 아포지질단백질 E의 발현 수준이 증가된 시험물질을 선별하는 단계;를 포함할 수 있다.A method for screening a hair loss improving agent according to the present invention comprises: treating a test substance in a biological sample isolated from a human body; Measuring the expression level of apolipoprotein E (ApoE) in the sample treated with the test substance; And comparing the expression level with the expression level of apolipoprotein E in a control group not treated with the test substance, and selecting a test substance having an increased expression level of the apolipoprotein E. It may include.
본 발명에 따른 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제는 갱년기, 난소절제 또는 난소 기능저하로 인한 탈모 증상 완화에 유의한 효과를 가진다.Apolipoprotein E (ApoE) or an inducer thereof according to the present invention has a significant effect on relieving symptoms of hair loss due to menopause, ovariectomy or ovarian decline.
이러한 효과를 가진 상기 아포지질단백질 E 또는 이의 유도제를 약학 조성물, 건강기능식품 조성물 및 화장료 조성물로 이용함으로써, 독성이나 부작용 없이 안전하게 갱년기, 난소절제 또는 난소 기능저하로 인한 탈모 증상을 보다 효과적으로 예방, 개선 및 치료할 수 있다.By using the apolipoprotein E or its inducer having such an effect as a pharmaceutical composition, a health functional food composition, and a cosmetic composition, more effectively preventing and improving hair loss symptoms caused by menopause, ovariectomy or ovarian function decline without toxicity or side effects. And can be treated.
도 1은 본 발명의 일 실험예에 따른 마우스의 탈모 변화를 나타낸다.1 shows a change in hair loss of a mouse according to an experimental example of the present invention.
이하, 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명자는 아포지질단백질 E의 결핍이 난소 기능 상실로 인한 탈모 증상을 가속화시킴을 확인함으로써, 본 발명을 완성하였다.The present inventor has completed the present invention by confirming that the deficiency of apolipoprotein E accelerates hair loss symptoms due to loss of ovarian function.
본 명세서에서 "예방"이란, 본 발명에 따른 약학 조성물, 건강기능식품 조성물 또는 화장료 조성물의 사용에 의해 탈모 또는 탈모의 적어도 하나 이상의 증상의 발생을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다. 또한, 재발을 예방하거나 방지하기 위해 상기 질병에 차도가 있는 대상의 치료를 포함한다.In the present specification, "prevention" refers to any action of inhibiting the occurrence of at least one symptom of hair loss or hair loss or delaying the onset by the use of the pharmaceutical composition, health functional food composition, or cosmetic composition according to the present invention. In addition, it includes treatment of a subject with remission of the disease to prevent or prevent recurrence.
본 명세서에서 "치료"란, 본 발명에 따른 약학 조성물의 투여에 의해 탈모 또는 탈모의 적어도 하나 이상의 증상을 완화, 감소, 또는 소멸시키는 등 그 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.In the present specification, "treatment" refers to all actions of improving or beneficially altering the symptoms such as alleviating, reducing, or eliminating at least one symptom of hair loss or hair loss by administration of the pharmaceutical composition according to the present invention.
본 명세서에서 "개선"이란, 본 발명에 따른 건강기능식품 조성물 또는 화장료 조성물의 사용에 의해 탈모 또는 탈모의 적어도 하나 이상의 증상이 완화, 감소, 또는 소멸시키는 등 그 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.In the present specification, the term "improvement" refers to alleviating, reducing, or eliminating at least one symptom of hair loss or hair loss by the use of the health functional food composition or cosmetic composition according to the present invention, etc. Means action.
본 명세서에서 "약학 조성물"이란, 특정한 목적을 위해 투여되는 조성물로, 본 발명의 목적상 탈모 또는 탈모의 적어도 하나 이상의 증상을 예방하거나 또는 치료하기 위해 투여되는 것을 의미한다.As used herein, the term "pharmaceutical composition" means a composition administered for a specific purpose, and for the purposes of the present invention, it is meant to be administered to prevent or treat at least one symptom of hair loss or hair loss.
본 명세서에서 "건강기능식품"이란, 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품으로, 영양 공급 외에도 생체 조절 기능이 효율적으로 나타나도록 가공된 의학, 의료 효과가 높은 식품을 의미하며 기능성 식품 등 당업계에 알려진 용어와 혼용할 수 있다.In the present specification, "health functional food" refers to foods manufactured and processed using raw materials or ingredients that have useful functionalities for the human body, and foods with high medical and medical effects processed to effectively show the biological control function in addition to supplying nutrition. It means and can be mixed with terms known in the art such as functional food.
본 명세서에서 "화장료"란, 탈모 개선 등의 효과를 가지는 기능성 화장료를 포함할 수 있고, 상기 기능성 화장료는 화장품법에 정의된 바에 따라 특정 효능과 효과가 강조된 화장료로 모발의 기능 약화 개선에 도움을 주거나 탈모 증상을 완화하는 것 등을 포함할 수 있다.In the present specification, the term "cosmetics" may include functional cosmetics having an effect of improving hair loss, and the functional cosmetics are cosmetics emphasizing specific effects and effects as defined in the Cosmetics Act to help improve the weakening of hair functions or It may include relieving symptoms of hair loss, and the like.
본 발명은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유하는 탈모 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating hair loss containing apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에서, "아포지질단백질 E(Apolipoprotein E; ApoE)"는 체내 지방의 대사에 관여하는 단백질의 한 종류로, 다른 아포지질단백질처럼 분자 내에 22개의 아미노산 반복 서열이 있어 양극성 나선(amphipathic helices)을 형성할 수 있고, 혈장 지질단백질의 표면과 결합할 수 있다. 아포지질단백질 E는 염기성 아미노산 잔기(136∼150)를 포함하고 있어 저밀도 지질단백질 수용체(low density lipoprotein receptor, LDL-R)에 잘 결합하며 이들 구조는 지질단백질 입자의 세포 내 이입(endocytosis)에 중요한 역할을 한다. In the present invention, "Apolipoprotein E (ApoE)" is a type of protein that is involved in the metabolism of fat in the body. Like other apolipoproteins, there are 22 amino acid repetitive sequences in the molecule, and thus bipolar helices (amphipathic helices) And can bind to the surface of plasma lipoproteins. Apolipoprotein E contains basic amino acid residues (136~150), so it binds well to the low density lipoprotein receptor (LDL-R), and these structures are important for endocytosis of lipoprotein particles. Plays a role.
또한, 아포지질단백질 E는 간세포뿐 아니라 거식세포(macrophage) 및 성상세포(astrocytes) 등에서도 합성될 수 있고, 중성지방(triglyceride)이 풍부한 카일로마이크론(triglyceride-rich chylomicron)과 초저밀도지질단백질(VLDL)의 잔유물(remnant)을 세포 내로 흡수하는 것을 촉진함으로써 지질단백 대사에 중요한 역할을 하기에, 아포지질단백질 E가 결핍된 넉아웃(knockout) 마우스(ApoE-/-)는 고지방식을 먹었을 때, 극단적인 고 콜레스테롤혈증을 일으킨다. In addition, apolipoprotein E can be synthesized not only in hepatocytes, but also in macrophages and astrocytes, and triglyceride-rich chylomicron and ultra-low-density lipoproteins ( Because it plays an important role in lipoprotein metabolism by promoting the absorption of the remnant of VLDL) into the cell, knockout mice (ApoE-/-) deficient in apolipoprotein E (ApoE-/-) eat a high-fat diet. , Causes extreme hypercholesterolemia.
본 발명에 따른 약학 조성물에 있어서, 상기 아포지질단백질 E는 탈모 증상을 개선하는데 유의한 효과를 가질 수 있다. 본 발명의 일 실험예에 따르면, 상기 아포지질단백질 E가 결핍된 마우스는 난소 기능 저하에 따른 탈모 증상이 더욱 촉진되는 것으로 나타났다.In the pharmaceutical composition according to the present invention, the apolipoprotein E may have a significant effect in improving hair loss symptoms. According to an experimental example of the present invention, the mouse deficient in the apolipoprotein E was found to further promote hair loss symptoms due to the decrease in ovarian function.
본 발명에 따른 약학 조성물에 있어서, 상기 유도제는 상기 아포지질단백질 E를 유도하고 이의 발현을 증가시킬 수 있는 miRNA 또는 화합물일 수 있으나, 이에 제한되는 것은 아니다. In the pharmaceutical composition according to the present invention, the inducing agent may be a miRNA or compound capable of inducing the apolipoprotein E and increasing its expression, but is not limited thereto.
상기 유도제는 예를 들어, AZ10606120, AZD9056 등의 화합물이 포함될 수 있다. 퓨린 수용체(purinergic receptor)인 P2X7에 높은 친화력을 가진 길항제(antagonist)로 알려진 AZ10606120은 아포지질단백질 E의 발현을 증가시킬 수 있다(Sci Rep 7:725). 또한, 이와 유사한 P2X7 길항제인 AZD9056 역시 아포지질단백질 E의 발현을 증가시킬 수 있어 상기 유도제로 사용될 수 있다. AZD9056은 현재 류마티스 관절염(rheumatic arthritis), 골관절염(osteoarthritis), 만성 폐쇄성 폐질환(chronic obstructive pulmonary disease), 크론병(Crohn’s Disease) 등을 치료하기 위한 임상 2단계에 사용되고 있다(Ann Rheum Dis 71:1630-1635).The inducing agent may include, for example, a compound such as AZ10606120 or AZD9056. AZ10606120, known as an antagonist with high affinity for P2X7, a purinergic receptor, can increase the expression of apolipoprotein E (Sci Rep 7:725). In addition, AZD9056, a similar P2X7 antagonist, can also increase the expression of apolipoprotein E, and thus can be used as the inducer. AZD9056 is currently being used in phase 2 clinical trials to treat rheumatic arthritis, osteoarthritis, chronic obstructive pulmonary disease, and Crohn's disease (Ann Rheum Dis 71:1630). -1635).
본 발명에 따른 약학 조성물에 있어서, 상기 아포지질단백질 E 또는 이의 유도제는 상기 단백질의 기능적 동등물 및 변이체를 포함할 수 있다. 상기 단백질의 기능적 동등물이란, 단백질 분자의 활성을 전체적으로 변경시키지 않는 단백질 및 폴리펩티드를 포함하는 것으로 기능적으로 동일한 작용을 할 수 있는 단백질이 포함될 수 있다. 또한, 상기 변이체란, 예를 들면 상기 아미노산 서열에서 하나 또는 수개의 아미노산이 결실, 치환 또는 부가된 것, 상기 아미노산 서열과 95% 이상, 바람직하게는 98% 이상, 보다 바람직하게는 99% 이상의 동일성을 갖는 것 등을 말한다.In the pharmaceutical composition according to the present invention, the apolipoprotein E or an inducer thereof may include a functional equivalent and a variant of the protein. The functional equivalent of the protein includes proteins and polypeptides that do not change the activity of the protein molecule as a whole, and proteins capable of functionally identical functions may be included. In addition, the variant refers to, for example, deletion, substitution, or addition of one or several amino acids in the amino acid sequence, 95% or more, preferably 98% or more, more preferably 99% or more identity with the amino acid sequence. It refers to having, etc.
본 발명에 따른 약학 조성물에 있어서, 상기 탈모는 갱년기, 난소 절제 또는 난소 기능저하로 인한 탈모일 수 있다. 즉, 상기 탈모는 폐경에 의한 갱년기 여성뿐만 아니라, 난소 절제 또는 난소 기능저하와 같은 다른 원인에 의한 에스트로겐 결핍 환자에서 발병한 탈모를 포함할 수 있다. In the pharmaceutical composition according to the present invention, the hair loss may be menopausal, ovarian resection, or hair loss due to ovarian decline. That is, the hair loss may include hair loss in menopausal women due to menopause, as well as in patients with estrogen deficiency due to other causes such as ovariectomy or ovarian function decline.
본 발명에 따른 약학 조성물은 약학적 분야의 통상적인 방법에 따라 제조될 수 있다.The pharmaceutical composition according to the present invention can be prepared according to a conventional method in the pharmaceutical field.
본 발명에 따른 약학 조성물은 상기 제형에 따라 약학적으로 허용가능한 적절한 담체와 배합될 수 있고, 필요에 따라, 부형제, 희석제, 분산제, 유화제, 완충제, 안정제, 결합제, 붕해제, 용제 등을 더 포함하여 제조할 수 있다. The pharmaceutical composition according to the present invention may be blended with an appropriate pharmaceutically acceptable carrier according to the above formulation, and further includes excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc., if necessary. It can be manufactured.
상기 "약학적으로 허용 가능한"이란, 상기 약학 조성물에 노출되는 세포나 인간에게 독성이 없는 것을 의미하고, 상기 적절한 담체 등은 본 발명에 따른 아포지질단백질 E 또는 이의 유도제의 활성 및 특성을 저해하지 않는 것으로, 투여 형태 및 제형에 따라 달리 선택될 수 있다.The "pharmaceutically acceptable" means that there is no toxicity to cells or humans exposed to the pharmaceutical composition, and the appropriate carrier or the like does not inhibit the activity and properties of the apolipoprotein E or its inducer according to the present invention. It may be selected differently depending on the dosage form and formulation.
본 발명에 따른 약학 조성물은 어떠한 제형으로도 적용될 수 있고, 보다 상세하게는 통상의 방법에 따라 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 비경구형 제형로 제형화하여 사용될 수 있다.The pharmaceutical composition according to the present invention may be applied in any dosage form, and more particularly, may be formulated and used in parenteral dosage forms of oral dosage forms, external preparations, suppositories, and sterile injectable solutions according to conventional methods.
상기 경구형 제형 중 고형 제형은 정제, 환제, 산제, 과립제, 캡슐제 등의 형태로, 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 솔비톨, 만니톨, 셀룰로오스, 젤라틴 등을 섞어 조제할 수 있고, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 포함될 수 있다. 또한, 캡술제형의 경우 상기 언급한 물질 외에도 지방유와 같은 액체 담체를 더 포함할 수 있다.Among the oral dosage forms, the solid dosage form may be in the form of tablets, pills, powders, granules, capsules, etc., and at least one excipient such as starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc. It can be prepared by mixing, and in addition to simple excipients, lubricants such as magnesium stearate and talc may also be included. In addition, in the case of the capsul formulation, in addition to the above-mentioned substances, a liquid carrier such as fatty oil may be further included.
상기 경구형 제형 중 액상 제형은 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Among the oral dosage forms, liquid dosage forms correspond to suspensions, liquid solutions, emulsions, syrups, and the like.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. may be included. have.
상기 비경구 제형은 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 이에 제한되지 않고, 당해 기술 분야에 알려진 적합한 제제를 모두 사용 가능하다.The parenteral formulation may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. may be used as the non-aqueous solvent and suspension. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used. The present invention is not limited thereto, and any suitable agent known in the art may be used.
또한, 본 발명에 따른 약학 조성물은 치료 효능의 증진을 위해 칼슘이나 비타민 D3 등을 더 첨가할 수 있다. In addition, the pharmaceutical composition according to the present invention may further include calcium or vitamin D 3 to improve therapeutic efficacy.
본 발명에 따른 약학 조성물에 있어서, 상기 약학 조성물은 약학적으로 유효한 양으로 투여될 수 있다. 상기 "약학적으로 유효한 양"이란, 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미한다.In the pharmaceutical composition according to the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount. The "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not cause side effects.
상기 약학 조성물의 유효 용량 수준은 사용 목적, 환자의 연령, 성별, 체중 및 건강 상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 달리 결정될 수 있다. 예를 들어, 일정하지는 않지만 일반적으로 0.001 내지 100mg/kg으로, 바람직하게는 0.01 내지 10mg/kg을 일일 1회 내지 수회 투여될 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 제한하는 것은 아니다.The effective dosage level of the pharmaceutical composition is the purpose of use, the patient's age, sex, weight and health condition, the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the administration time, the administration route and the rate of excretion, the treatment It may be determined differently depending on the duration, factors including drugs used in combination or concurrently and other factors well known in the medical field. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg may be administered once to several times a day. The above dosage does not in any way limit the scope of the present invention.
본 발명에 따른 약학 조성물은 탈모가 발생할 수 있는 임의의 동물에 투여할 수 있고, 상기 동물은 예를 들어, 인간 및 영장류뿐만 아니라 소, 돼지, 말, 개 등의 가축 등을 포함할 수 있다.The pharmaceutical composition according to the present invention may be administered to any animal that may cause hair loss, and the animal may include, for example, humans and primates as well as livestock such as cattle, pigs, horses, and dogs.
본 발명에 따른 약학 조성물은 제제 형태에 따른 적당한 투여 경로로 투여될 수 있고, 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 투여 방법은 특히 한정할 필요 없이, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 기관지내 흡입, 자궁내 경막 또는 뇌혈관내(intracere-broventricular) 주사 등의 통상적인 방법으로 투여될 수 있다.The pharmaceutical composition according to the present invention can be administered by an appropriate route of administration according to the form of the formulation, and can be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. The method of administration is not particularly limited and may be administered by conventional methods such as, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrabronchial inhalation, intrauterine dura mater or intracere-broventricular injection. .
본 발명에 따른 약학 조성물은 탈모 예방 또는 치료를 위하여 단독으로 사용될 수 있고, 수술 또는 다른 약물 치료 등과 병용하여 사용될 수 있다.The pharmaceutical composition according to the present invention may be used alone to prevent or treat hair loss, or may be used in combination with surgery or other drug treatment.
본 발명은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유하는 탈모 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or improving hair loss containing apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 탈모는 갱년기, 난소 절제 또는 난소 기능저하로 인한 탈모일 수 있다. 즉, 상기 탈모는 폐경에 의한 갱년기 여성뿐만 아니라, 난소 절제 또는 난소 기능저하와 같은 다른 원인에 의한 에스트로겐 결핍 환자에서 발병한 탈모를 포함할 수 있다. In the health functional food composition according to the present invention, the hair loss may be hair loss due to menopause, ovarian resection, or ovarian decline. That is, the hair loss may include hair loss in menopausal women due to menopause, as well as in patients with estrogen deficiency due to other causes such as ovariectomy or ovarian function decline.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 건강기능식품은 분말, 과립, 정제, 캡슐, 시럽 또는 음료 등으로 제조될 수 있고, 상기 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있다. 예를 들어, 음료 및 각종 드링크, 과실 및 그의 가공식품(과일통조림, 잼 등), 어류, 육류 및 그 가공식품(햄, 베이컨 등), 빵류 및 면류, 쿠키 및 스낵류, 유제품(버터, 치즈 등) 등이 가능하며, 통상적인 의미에서의 기능성 식품을 모두 포함할 수 있다. 또한, 동물을 위한 사료로 이용되는 식품도 포함할 수 있다.In the health functional food composition according to the present invention, the health functional food may be prepared as a powder, granule, tablet, capsule, syrup or beverage, and there is no limitation on the form that the health functional food can take. It can include all foods of meaning. For example, beverages and various drinks, fruits and processed foods thereof (canned fruit, jam, etc.), fish, meat and processed foods thereof (ham, bacon, etc.), bread and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), and the like, and may include all functional foods in the usual sense. In addition, foods used as feed for animals may also be included.
본 발명에 따른 건강기능식품 조성물은 당업계에서 통상적으로 사용되는 식품학적으로 허용 가능한 식품 첨가제 및 적절한 기타 보조 성분을 더 포함하여 제조될 수 있다. 예를 들어, 향미제, 천연 탄수화물, 감미제, 비타민, 전해질, 착색제, 펙트산, 알긴산, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산화제 등을 추가로 함유할 수 있다. 특히, 상기 천연 탄수화물로는 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜을 사용할 수 있으며, 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food composition according to the present invention may be prepared further comprising a food pharmaceutically acceptable food additive and other appropriate auxiliary ingredients commonly used in the art. For example, flavoring agents, natural carbohydrates, sweetening agents, vitamins, electrolytes, colorants, pectic acids, alginic acids, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents, etc. I can. In particular, as the natural carbohydrates, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol may be used. , As the sweetener, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
본 발명에 따른 건강기능식품 조성물은 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 탈모 예방 또는 개선을 위한 보조제로 섭취될 수 있다.The health functional food composition according to the present invention has the advantage of not having side effects that may occur when taking the drug for a long period of time unlike general drugs, and it is excellent in portability, and can be taken as an adjuvant for preventing or improving hair loss. I can.
본 발명은 아포지질단백질 E(Apolipoprotein E; ApoE) 또는 이의 유도제를 유효성분으로 함유하는 탈모 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving hair loss, comprising apolipoprotein E (ApoE) or an inducer thereof as an active ingredient.
본 발명에 따른 화장료 조성물에 있어서, 상기 탈모는 갱년기, 난소 절제 또는 난소 기능저하로 인한 탈모일 수 있다. 즉, 상기 탈모는 폐경에 의한 갱년기 여성뿐만 아니라, 난소 절제 또는 난소 기능저하와 같은 다른 원인에 의한 에스트로겐 결핍 환자에서 발병한 탈모를 포함할 수 있다. In the cosmetic composition according to the present invention, the hair loss may be hair loss due to menopause, ovarian resection, or ovarian decline. That is, the hair loss may include hair loss in menopausal women due to menopause, as well as in patients with estrogen deficiency due to other causes such as ovariectomy or ovarian function decline.
본 발명에 따른 화장료 조성물은 피부 외용제 제형으로, 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 모발건조제, 모발보존처리제, 모발 염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 및 헤어스프레이로 이루어진 군에서 선택되는 어느 하나의 제형일 수 있으나, 이에 제한되지는 않는다.The cosmetic composition according to the present invention is a skin external preparation formulation, hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair Massage cream, hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair dryer, hair preservation agent, hair dye, hair wave agent, hair bleach, hair gel, hair glaze, hairdresser, hair lacquer , Hair moisturizer, hair mousse, and may be any one formulation selected from the group consisting of hair spray, but is not limited thereto.
또한, 본 발명에 따른 화장료 조성물은 상기 유효성분 이외에 통상적으로 허용되는 성분들을 제한 없이 포함할 수 있으며, 예를 들어, 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다. 또한, 상기 화장료 조성물은 그 효과를 증진시키기 위해 피부 흡수 촉진제를 추가로 포함할 수 있다.In addition, the cosmetic composition according to the present invention may include, without limitation, ingredients that are commonly allowed in addition to the active ingredients, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, And it may include a carrier. In addition, the cosmetic composition may further include a skin absorption accelerator to enhance its effect.
본 발명에 따른 화장료 조성물에 있어서, 상기 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성 오일, 식물성 오일, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.In the cosmetic composition according to the present invention, when the formulation of the cosmetic composition is a paste, cream or gel, as a carrier component, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, Silica, talc, or zinc oxide may be used.
상기 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴라아미드 파우더가 이용될 수 있으며, 특히 스프레이인 경우에는 추가적으로 클로로 플루오로 히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, Propellants such as propane/butane or dimethyl ether.
상기 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예를 들어, 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤지방족에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르를 들 수 있다.When the formulation of the cosmetic composition is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.
상기 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌소르비톨에스테르 및 폴리옥시에틸렌소르비탄에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
또한, 본 발명에 따른 화장료 조성물은 모발에 도포하기에 적당한 캐리어 또는 캐리어 혼합물을 포함하여 모발 보호 조성물로 제조될 수 있다. 캐리어는 용매와 다른 캐리어 또는 모발 보호 조성물에 통상적으로 사용되는 비히클(vehicle) 성분을 포함하며, 전체 조성물의 조성물 중 약 0.5% 내지 99.5%, 바람직하게는 약 5.0% 내지 99.5%, 가장 바람직하게는 약 10.0% 내지 90.0%로 존재할 수 있다.In addition, the cosmetic composition according to the present invention may be prepared as a hair protection composition including a carrier or a carrier mixture suitable for application to hair. The carrier comprises a carrier component other than a solvent or a vehicle component commonly used in hair care compositions, and is about 0.5% to 99.5%, preferably about 5.0% to 99.5%, most preferably, of the composition of the total composition. It may be present at about 10.0% to 90.0%.
캐리어로서 용매는 제형화된 모발 보호 조성물이 헤어 스프레이, 무스, 토닉 등과 같이 사용 후 모발에 남는 것이거나 샴푸, 컨디셔너 등과 같이 세정되는 것에 관계없이 사용하는 공중합체에 의해 선택될 수 있다. 예를 들어, 물, 저급 알코올(에탄올, 이소프로판올 등), 하이드로알콜계 혼합물, 탄화수소(이소부탄, 헥산, 데센등), 아세톤, 할로겐화 탄화수소(프레온 등), 탄화수소 에스테르(에틸 아세테이트, 디부틸프탈레이트 등), 휘발성 실리콘 유도체, 실록산(페닐 펜타메틸 디실록산, 메톡시프로필 헵타메틸 사이클로테트라실록산, 클로로프로필 펜타메틸 디실록산, 하이드록시프로필 펜타메틸디실록산, 옥타메틸 사이클로테트라실록산, 데카메틸 사이클로펜타실록산 등) 및 이들의 혼합물로 이루어진 군에서 선택될 수 있으나, 이에 제한되는 것은 아니다.The solvent as a carrier may be selected by the copolymer used regardless of whether the formulated hair protection composition remains on the hair after use, such as hair spray, mousse, tonic, or the like, or is cleaned such as shampoo, conditioner, and the like. For example, water, lower alcohols (ethanol, isopropanol, etc.), hydroalcohol mixtures, hydrocarbons (isobutane, hexane, decene, etc.), acetone, halogenated hydrocarbons (freon, etc.), hydrocarbon esters (ethyl acetate, dibutylphthalate, etc.) ), volatile silicone derivatives, siloxanes (phenyl pentamethyl disiloxane, methoxypropyl heptamethyl cyclotetrasiloxane, chloropropyl pentamethyl disiloxane, hydroxypropyl pentamethyldisiloxane, octamethyl cyclotetrasiloxane, decamethyl cyclopentasiloxane, etc.) ) And may be selected from the group consisting of a mixture thereof, but is not limited thereto.
본 발명은 아포지질단백질 E(Apolipoprotein E; ApoE) 발현을 이용한 탈모 개선제 스크리닝 방법을 제공한다.The present invention provides a method for screening a hair loss improving agent using Apolipoprotein E (ApoE) expression.
상기 탈모 개선제 스크리닝 방법은 탈모 개선제 후보 물질의 존재 및 부재 하에서 상기 단백질의 발현 수준의 증가 또는 감소를 비교하는 방법으로, 탈모 증상을 개선하는 탈모 개선제 후보 물질을 스크리닝하는데 유용하게 사용될 수 있다.The hair loss improving agent screening method is a method of comparing the increase or decrease of the expression level of the protein in the presence and absence of a hair loss improving agent candidate material, and may be usefully used for screening a hair loss improving agent candidate material that improves hair loss symptoms.
본 발명에 따른 탈모 개선제 스크리닝 방법은 인체에서 분리된 생물학적 시료에 시험물질을 처리하는 단계; 상기 시험물질을 처리한 시료에서 아포지질단백질 E(Apolipoprotein E; ApoE) 발현 수준을 측정하는 단계; 및 상기 발현 수준을 상기 시험물질을 처리하지 않은 대조군에서의 아포지질단백질 E의 발현 수준과 비교하여, 상기 아포지질단백질 E의 발현 수준이 증가된 시험물질을 선별하는 단계;를 포함할 수 있다.A method for screening a hair loss improving agent according to the present invention comprises: treating a test substance in a biological sample isolated from a human body; Measuring the expression level of apolipoprotein E (ApoE) in the sample treated with the test substance; And comparing the expression level with the expression level of apolipoprotein E in a control group not treated with the test substance, and selecting a test substance having an increased expression level of the apolipoprotein E. It may include.
본 발명에 따른 탈모 개선제 스크리닝 방법에 있어서, 상기 인체에서 분리된 생물학적 시료는 상기 단백질의 발현 수준이 정상 대조군과 차이가 나는 조직, 세포, 전혈, 혈청, 혈장 또는 타액 등을 포함할 수 있으나, 이에 제한되는 것은 아니다. In the hair loss improving agent screening method according to the present invention, the biological sample isolated from the human body may include tissues, cells, whole blood, serum, plasma, saliva, etc., in which the expression level of the protein is different from that of the normal control group. It is not limited.
본 발명에 따른 탈모 개선제 스크리닝 방법에 있어서, 상기 시험물질은 상기 단백질의 발현 수준에 영향을 미치는지 여부를 검사하기 위하여 스크리닝에 이용되는 물질로, 탈모 증상 개선을 위한 후보 약물, 즉 탈모 개선제일 수 있다.In the method for screening a hair loss improving agent according to the present invention, the test substance is a substance used for screening to examine whether or not it affects the expression level of the protein, and may be a candidate drug for improving hair loss symptoms, that is, a hair loss improving agent. .
본 발명에 따른 탈모 개선제 스크리닝 방법에 있어서, 상기 탈모는 갱년기, 난소 절제 또는 난소 기능저하로 인한 탈모일 수 있다. 즉, 상기 탈모는 폐경에 의한 갱년기 여성뿐만 아니라, 난소 절제 또는 난소 기능저하와 같은 다른 원인에 의한 에스트로겐 결핍 환자에서 발병한 탈모를 포함할 수 있다. In the method for screening a hair loss improving agent according to the present invention, the hair loss may be hair loss due to menopause, ovarian resection, or ovarian function decline. That is, the hair loss may include hair loss in menopausal women due to menopause, as well as in patients with estrogen deficiency due to other causes such as ovariectomy or ovarian function decline.
본 발명에 따른 탈모 개선제 스크리닝 방법에 있어서, 상기 단백질 발현 수준은 웨스턴 블랏, 효소면역분석법(Enzymelinked immunosorbent assay; ELISA), 방사선면역분석(Radioimmunoassay; RIA), 방사면역 확산법(Radioimmunodiffusion), 오우크테로니(Ouchterlony) 면역 확산법, 로케트(rocket) 면역 전기영동, 조직면역염색, 면역침전 분석법(Immunoprecipitation assay), 보체고정분석법(Complement Fixation Assay), 유세포분석법(Fluorescence Activated Cell Sorter, FACS) 및 단백질 칩(protein chip)으로 이루어진 군에서 선택된 어느 하나 이상의 방법으로 측정될 수 있으나, 이에 제한되는 것은 아니다.In the hair loss improving agent screening method according to the present invention, the protein expression level is Western blot, Enzymelinked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion method (Radioimmunodiffusion), Ouchteroni (Ouchterlony) Immune diffusion method, rocket immunoelectrophoresis, tissue immunostaining, Immunoprecipitation assay, Complement Fixation Assay, Fluorescence Activated Cell Sorter (FACS) and protein chip chip) may be measured by any one or more methods selected from the group consisting of, but is not limited thereto.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to aid understanding of the present invention. However, the following examples are for illustrative purposes only, and the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
<실험예 1> ApoE 결핍에 따른 난소기능저하에 의한 탈모 촉진 효과 확인<Experimental Example 1> Confirmation of the effect of promoting hair loss due to decreased ovarian function due to ApoE deficiency
1. 실험방법1. Experiment method
10주령의 암컷 C57BL/6J 마우스를 대상으로, 2’,2’,2’-트리브로모에탄올(2’,2’,2’-tribromoethanol, 250 mg/kg, Sigma Chemical)을 이용하여 마취 하에 모의 수술(sham operation) 또는 난소절제술(OVX)을 시행하였다. 10 weeks old female C57BL/6J mice under anesthesia using 2',2',2'-tribromoethanol (2',2',2'-tribromoethanol, 250 mg/kg, Sigma Chemical) A sham operation or ovariectomy (OVX) was performed.
C57BL/6J 유전적 배경(genetic background) ApoE-/- (ApoE 넉아웃, KO) 마우스는 잭슨 연구소(Jackson Laboratory)에서 구입되었다. 마우스는 울산대학교의 동물 시설에서 사육되었고, 물과 표준 식사 식단에 자유롭게 접근할 수 있는 특정 병원균이 없는 상태를 유지하였다.C57BL/6J genetic background ApoE-/- (ApoE knockout, KO) mice were purchased from Jackson Laboratory. Mice were bred in an animal facility at the University of Ulsan, and were kept free of specific pathogens with free access to water and standard dietary diets.
수술 후, 8주 동안 마우스는 죽종 조절 식단(atherogenic diet)을 수행하였다. 1.25%의 콜레스테롤(cholesterol), 16% 지방(fat) 및 0.5% 콜레이트(cholate)를 포함하는 마우스 죽종 조절 식단은 리서치 다이어트(Research Diets, Inc, New Brunswick, NJ, USA)에서 구입되었다. After surgery, for 8 weeks, the mice were subjected to an atherogenic diet. A mouse atheroma-controlled diet comprising 1.25% cholesterol, 16% fat and 0.5% cholate was purchased from Research Diets, Inc, New Brunswick, NJ, USA.
성별 및 연령이 일치하는 한배새끼(littermate)를 대조군으로 하였다. Littermates having the same sex and age were used as controls.
모든 동물 관리 및 절차는 울산대학교 동물실험윤리위원회(UOUACUC)의 승인을 받은 프로토콜 및 가이드라인에 따라 수행되었다(HSC-14-060).All animal care and procedures were performed according to protocols and guidelines approved by the University of Ulsan Animal Experimental Ethics Committee (UOUACUC) (HSC-14-060).
2. 실험 결과2. Experiment result
도 1은 본 발명의 일 실험예에 따른 마우스의 탈모 변화를 나타낸다.1 shows a change in hair loss of a mouse according to an experimental example of the present invention.
도 1을 참조하면, 8 주 수술 후 난소 절제술을 시행한 ApoE 결핍 마우스(ApoE-KO)에서는 극단적인 탈모가 관찰되었지만, 대조군(WT) 마우스에서는 그렇지 않았다. 이를 통해 ApoE 결핍이 난소 기능의 상실로 인한 탈모를 가속화시킴을 확인할 수 있었다.Referring to FIG. 1, extreme hair loss was observed in ApoE-deficient mice (ApoE-KO) subjected to oophorectomy after 8 weeks of surgery, but not in control (WT) mice. Through this, it was confirmed that ApoE deficiency accelerated hair loss due to loss of ovarian function.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, it is obvious that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereby. Do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (9)
상기 유도제는,
상기 아포지질단백질 E를 유도할 수 있는 miRNA 또는 화합물인 것을 특징으로 하는 탈모 예방 또는 치료용 약학 조성물.The method of claim 1,
The inducing agent,
A pharmaceutical composition for preventing or treating hair loss, characterized in that it is a miRNA or compound capable of inducing the apolipoprotein E.
상기 탈모는,
갱년기, 난소절제 또는 난소 기능저하로 인한 탈모인 것을 특징으로 하는 탈모 예방 또는 치료용 약학 조성물.The method of claim 1.
The hair loss,
Hair loss prevention or treatment pharmaceutical composition, characterized in that the hair loss due to menopause, ovariectomy or ovarian function decline.
상기 탈모는,
갱년기, 난소절제 또는 난소 기능저하로 인한 탈모인 것을 특징으로 하는 탈모 예방 또는 개선용 건강기능식품 조성물.The method of claim 4.
The hair loss,
Hair loss prevention or improvement health functional food composition, characterized in that the hair loss due to menopause, ovariectomy or ovarian function decline.
상기 탈모는,
갱년기, 난소절제 또는 난소 기능저하로 인한 탈모인 것을 특징으로 하는 탈모 예방 또는 개선용 화장료 조성물.The method of claim 6.
The hair loss,
Hair loss prevention or improvement cosmetic composition, characterized in that the hair loss due to menopause, ovariectomy or ovarian function decline.
상기 시험물질을 처리한 시료에서 아포지질단백질 E(Apolipoprotein E; ApoE) 발현 수준을 측정하는 단계; 및
상기 발현 수준을 상기 시험물질을 처리하지 않은 대조군에서의 아포지질단백질 E의 발현 수준과 비교하여, 상기 아포지질단백질 E의 발현 수준이 증가된 시험물질을 선별하는 단계;를 포함하는 것을 특징으로 하는 탈모 개선제 스크리닝 방법.Treating the test substance on the biological sample isolated from the human body;
Measuring the expression level of apolipoprotein E (ApoE) in the sample treated with the test substance; And
Comprising the step of comparing the expression level with the expression level of apolipoprotein E in a control group not treated with the test substance, and selecting a test substance having an increased expression level of the apolipoprotein E; characterized in that it comprises a. Hair loss improving agent screening method.
상기 탈모는,
갱년기, 난소절제 또는 난소 기능저하로 인한 탈모인 것을 특징으로 하는 탈모 개선제 스크리닝 방법. The method of claim 8,
The hair loss,
Hair loss improving agent screening method, characterized in that the hair loss due to menopause, ovariectomy or decreased ovarian function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190028105A KR102234320B1 (en) | 2019-03-12 | 2019-03-12 | Composition for preventing, improving or treating hair loss comprising apolipoprotein e |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190028105A KR102234320B1 (en) | 2019-03-12 | 2019-03-12 | Composition for preventing, improving or treating hair loss comprising apolipoprotein e |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200109071A true KR20200109071A (en) | 2020-09-22 |
| KR102234320B1 KR102234320B1 (en) | 2021-03-31 |
Family
ID=72706729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190028105A KR102234320B1 (en) | 2019-03-12 | 2019-03-12 | Composition for preventing, improving or treating hair loss comprising apolipoprotein e |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102234320B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160121122A (en) | 2015-04-10 | 2016-10-19 | 차의과학대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth |
-
2019
- 2019-03-12 KR KR1020190028105A patent/KR102234320B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160121122A (en) | 2015-04-10 | 2016-10-19 | 차의과학대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102234320B1 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101360817B1 (en) | A drug for treating or preventing arteriosclerosis | |
| KR101797813B1 (en) | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient | |
| US10975130B2 (en) | Composition for preventing hair loss or promoting hair growth | |
| EP3326638A1 (en) | Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa | |
| KR102124986B1 (en) | Composition for prevention or treatment of muscular disorder or improvement of muscular functions comprising Leonurus japonicus extract or leonurine | |
| JP7149548B2 (en) | Composition for prevention, improvement or treatment of muscle diseases, or for improving muscle function, containing an extract of damselfly | |
| KR101733065B1 (en) | Composition comprising Decanal or as active ingredients for preventing hair loss or stimulating hair growth | |
| JPWO2006033351A1 (en) | Composition for inducing thioredoxin expression | |
| US20190216707A1 (en) | Composition for preventing hair loss and promoting hair growth, comprising phytoestrogen as an active ingredient | |
| KR102239075B1 (en) | Composition for Preventing or Treating Sarcopenia Comprising IF1 | |
| KR102234320B1 (en) | Composition for preventing, improving or treating hair loss comprising apolipoprotein e | |
| JP6660668B2 (en) | UCP-1 expression promoter | |
| AU2009206092A1 (en) | Combination therapy comprising actinidia and steroids and uses thereof | |
| JP5923375B2 (en) | CGRP response promoter | |
| JP2019043928A (en) | Composition comprising protectin dx as active ingredient for preventing or treating hyperlipidemia or fatty liver disease | |
| JP6553375B2 (en) | UCP-1 expression promoter | |
| KR102276379B1 (en) | Composition for Preventing or Treating Bone Diseases Comprising IF1 | |
| JP2007077051A (en) | New compound, obesity improver, lipid metabolism improver, hypoglycemic agent, and hair growth improver | |
| US10426769B2 (en) | Pharmaceutical composition for preventing and treating obesity or liver diseases, containg TLR7 agonist | |
| US20210000793A1 (en) | Composition for preventing or treating hair loss | |
| KR102118953B1 (en) | GV1001 as therapeutic drugs or composites for prevention and treatment of osteoporesis | |
| KR101844816B1 (en) | Composition For Improving Or Treating Anorexia Including Guanabenz And Method Using Thereof | |
| JP2011006347A (en) | Fat cell differentiation inhibitor and use thereof | |
| JPH1045572A (en) | Magnolol-containing synthetic suppressor of protein belonging to hsp27 family | |
| EP3903803A1 (en) | Pharmaceutical composition comprising pibf protein as active ingredient for prevention or treatment of inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |